Semaglutide, but not naltrexone plus bupropion, was associated with a significantly lower risk of MACE and acute myocardial infarction in patients with established CVD, whereas cardiovascular mortality was reduced by naltrexone plus bupropion but not by semaglutide
However, this may be due to BPC 157s clinical infancy and the limited number of published clinical trial articles exploring the use of the peptide
Its also possible to have heartburn or acid reflux
A glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon triple agonist, Tirzepitide targets multiple physiological pathways involved in appetite regulation and glucose metabolism
Its unique pharmacology allows researchers to investigate appetite regulation, glucose metabolism, lipid utilization, and energy expenditure within a single experimental model